Elite Pharmaceuticals and SunGen Pharma File ANDA for Extended-Release CNS Stimulant
30 mai 2018 07h30 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche...
Elite Pharmaceuticals Announces Strategic Marketing Alliance with Glenmark Pharmaceuticals, Inc., USA
29 mai 2018 07h30 HE
|
Elite Pharmaceuticals, Inc.; Glenmark Pharmaceuticals, Inc., USA
NORTHVALE, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc (OTCBB:ELTP) announced today the signing of a license, manufacturing, and supply agreement with Glenmark Pharmaceuticals,...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2018 Ended December 31, 2017
09 févr. 2018 16h57 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Elite Pharmaceuticals and SunGen Pharma File ANDA
08 févr. 2018 11h32 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche...
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss Third Quarter Financial Results on February 12, 2018
07 févr. 2018 07h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals Reports Positive Topline Results from SequestOx™ Pilot Study
30 janv. 2018 08h35 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from a pilot study conducted for...
Elite Pharmaceuticals Reports Positive Topline Results from Pivotal Bioequivalence Studies for an Extended-Release Generic
10 janv. 2018 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from pivotal bioequivalence studies for...
Elite Pharmaceuticals Announces FDA Approval of Phendimetrazine Tartrate Tablets USP
02 janv. 2018 12h56 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2018 Ended September 30, 2017
09 nov. 2017 16h59 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
CORRECTING and REPLACING – Elite Pharmaceuticals, Inc.
07 nov. 2017 10h27 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- In a release issued earlier today by Elite Pharmaceuticals, Inc. (OTCQB:ELTP), please note in the headline the conference call date should be...